Kadmon (KDMN) Stock Price Down 5.5%
Kadmon Holdings Inc (NYSE:KDMN) shares traded down 5.5% on Thursday . The stock traded as low as $2.73 and last traded at $2.74. 759,534 shares changed hands during mid-day trading, a decline of 21% from the average session volume of 965,665 shares. The stock had previously closed at $2.90.
Several research analysts recently weighed in on the stock. HC Wainwright reissued a “buy” rating and issued a $25.00 target price on shares of Kadmon in a research note on Tuesday. Citigroup raised shares of Kadmon from a “neutral” rating to a “buy” rating and set a $2.77 target price for the company in a research note on Tuesday, February 26th. Finally, Zacks Investment Research downgraded shares of Kadmon from a “buy” rating to a “hold” rating in a research note on Saturday, February 23rd. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $8.36.
The company has a market cap of $371.85 million, a price-to-earnings ratio of -1.93 and a beta of 2.83. The company has a debt-to-equity ratio of 0.60, a quick ratio of 4.08 and a current ratio of 4.12.
Hedge funds have recently made changes to their positions in the stock. Amalgamated Bank acquired a new position in shares of Kadmon during the 4th quarter valued at about $25,000. Capital Investment Advisors LLC acquired a new position in shares of Kadmon during the 4th quarter valued at about $26,000. IFP Advisors Inc increased its stake in shares of Kadmon by 54.5% during the 4th quarter. IFP Advisors Inc now owns 25,500 shares of the company’s stock valued at $49,000 after acquiring an additional 9,000 shares during the last quarter. Metropolitan Life Insurance Co. NY increased its stake in shares of Kadmon by 356.6% during the 4th quarter. Metropolitan Life Insurance Co. NY now owns 26,251 shares of the company’s stock valued at $55,000 after acquiring an additional 20,502 shares during the last quarter. Finally, New York State Common Retirement Fund increased its stake in shares of Kadmon by 71.5% during the 4th quarter. New York State Common Retirement Fund now owns 88,500 shares of the company’s stock valued at $184,000 after acquiring an additional 36,900 shares during the last quarter. 71.96% of the stock is owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION WARNING: This news story was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright law. The original version of this news story can be read at https://www.watchlistnews.com/kadmon-kdmn-stock-price-down-5-5/2890613.html.
Kadmon Company Profile (NYSE:KDMN)
Kadmon Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. The company markets and distributes a portfolio of branded generic ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including tetrabenazine for the treatment of chorea associated with Huntington's disease.
Featured Article: What is a Swap?
Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.